HI RYNZN
That is not a question you should be asking me, but i have previously answered anyway just take a look at our proposed PH2 through the EMA
Then go ask the company WHY
Please note i did not ask for the increased dose it was the companies preference to move forwards
Please note THE EMA key trial parameters is the inclusion of a 25mg dosing Arm, goes onto to say they ANP are now looking to include the 25mg dosing into the trial
30 July 2020 European Medicines Agency DMD Scientific Advice and Regulatory Process Update • EMA feedback reflects the prior scientific advice from the three EU national authorities on appropriateness of key trial design parameters • Inclusion of 25mg dosing arm into the study given demonstrated efficacy in Phase II • Company to define clinical and regulatory pathway in the US as a priority Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY], (the Company) is pleased to advise that the European Medicines Agency (EMA) feedback reflects the prior scientific advice received from the three European Union national authorities on the appropriateness of the key trial design parameters of dose duration, safety monitoring plan, endpoints, and potential pivotal status for the planned Phase IIb study of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD). In light of the positive Phase II trial results, the Company is now looking to include a 25mg dosing arm into the Phase IIb trial with the view that this could be a clinically effective dose in this study. The EMA advised that further rationale be provided for the selection of the proposed higher dose levels (up to 100mg per week) and for consideration to be given to the use of intermediate doses and an increase to the sample size (to around 35 patients per arm).
We all think this is fantastic, but what do you not understand that a controlled higher dosing could well improve results out off site
And if they don't then as i have previously stated we will be running the 25mg dosing along side
Do your research
Look and listen to what Pat had to say she was expecting Mg per Kg weight ratio
And yes i can understand Pats way of thinking
Go back to our 1103 studies and you will find that the company could basically define results and project outcomes not through Mg per wk but by Mg per Kg dosage
IE the bigger patients showed less effect than the smaller patients this was worked out from clinical results
This is what the trials are all about to control disease in patients without toxing them out and causing further problems
You make it sound like a ridiculous statement that we should include higher dosing, much the same as you did when you inferred it would be all over red rover with one meeting with the FDA, which is obviously not the case at hand
Anyway i am happy with my own research and from now on will keep my assumption's and and findings to myself sick of seeing the roses and rainbows some people on here need a reality check
GL with your investments
HULK dosing what a joke
- Forums
- ASX - By Stock
- PER
- Ann: US FDA Type C Meeting for ATL1102 in DMD
Ann: US FDA Type C Meeting for ATL1102 in DMD, page-66
-
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
7.9¢ | 8.0¢ | 7.7¢ | $41.16K | 516.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 74175 | 7.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 1272 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 74175 | 0.079 |
1 | 69866 | 0.074 |
1 | 75000 | 0.073 |
1 | 53000 | 0.071 |
2 | 15000 | 0.070 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 1272 | 1 |
0.081 | 198015 | 2 |
0.082 | 33389 | 1 |
0.084 | 343300 | 4 |
0.085 | 263000 | 1 |
Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |